ALOGLIPTIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21N5O2
Molecular Weight	339.3916
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O

InChI

InChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N

InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H21N5O2
Molecular Weight	339.3916
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.takeda.com/news/2013/20130924_5997.html; http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase 4 8 Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s009lbl.pdf	Secondary		Approved 8583	NESINA Approved Use Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. Launch Date 2013

C_max

Value	Dose	Analyte	Population
75.38 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
154.83 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
335.36 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
55.28 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
114.08 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
246 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
842.17 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1625.58 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
3389.21 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
895.28 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
601.65 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1674.88 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1174.76 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
3306.68 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
2488.48 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
1511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
20.67 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
19.45 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
17 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663	50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered:	ALOGLIPTIN plasma	Homo sapiens population: healthy age: Adults sex: food status:
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
21 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
80% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		[NO STEREO] ALOGLIPTIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18405789	healthy, 26.6 years (range: 18-55 years) Health Status: healthy Age Group: 26.6 years (range: 18-55 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/18405789	Sources: https://pubmed.ncbi.nlm.nih.gov/18405789
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/	unhealthy, 55.6 years (range: 18 - 75 years) Health Status: unhealthy Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/	Other AEs: Headache, Dizziness... Other AEs: Headache (6 patients) Dizziness (4 patients) Constipation (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18405788/
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf	Disc. AE: Acute myocardial infarction, Angina unstable... AEs leading to discontinuation/dose reduction: Acute myocardial infarction (8 patients) Angina unstable (2 patients) Myocardial infarction (12 patients) Abdominal pain (2 patients) Diarrhea (1 patient) Nausea (3 patients) Edema peripheral (4 patients) Blood creatinine increased (6 patients) Creatinine renal clearance abnormal (3 patients) Creatinine renal clearance decreased (22 patients) Lipase increased (10 patients) Hyperglycemia (3 patients) Dizziness (4 patients) Headache (2 patients) Renal impairment (13 patients) Rash (2 patients) Rash pruritic (3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438 inducer 440	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057 CYP3A4/5 296 OAT1 725 OAT3 747 OCT2 779	P-gp 2052 OAT1 395 OAT3 391 OCT2 434	CYP1A2 832 CYP2B6 669 CYP2C19 329 CYP3A4/5 133

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166.0	little or no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no [IC50 78 uM]	no (co-administration study) Comment: mechanism-based inhibition using midazolam; did not change in vivo 3A4 substrates (midazolam and atorvastatin exposure) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	no
OAT1 730	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OAT3 749	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OCT2 782	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0	some [IC50 >100 uM]	weak (co-administration study) Comment: increased dextromethorphan AUC by 26% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=165 Page: 165.0
CYP3A4/5 357	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166;62	yes	no (co-administration study) Comment: induction at 100 µM was 27.6% as effective as rifampin; did not affect exposure of 3A4 substrates (midazolam and atorvastatin) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166;62

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0	inconclusive	no (co-administration study) Comment: cyclosporin does not have significant impact on plasma PK of SYR-322 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0
OAT1 395	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OAT3 391	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
OCT2 434	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136081/	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000PharmR.pdf#page=109 Page: 109.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:72323	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:72323
ChemicalBook	CB91011068	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91011068
eMolecules	31229135	https://www.emolecules.com/cgi-bin/more?vid=31229135
MolPort	MolPort-005-933-065	https://www.molport.com/shop/molecule-link/MolPort-005-933-065
Selleck Chemicals	alogliptin-syr-322	http://www.selleckchem.com/products/alogliptin-syr-322.html
ZINC	ZINC000014961096	http://zinc15.docking.org/substances/ZINC000014961096

PubMed

Title	Date	PubMed
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.	2012-08-01	22686547
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.	2012-06	22475866
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.	2010-12	21246005
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.	2010-12	20843518
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.	2010-11	20879969
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.	2010-11	20724648
DPP-4 inhibitors: what may be the clinical differentiators?	2010-11	20708812
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.	2010-10-22	20883057
Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.	2010-10	21335294
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.	2010-09-07	20859539
Exenatide once weekly: clinical outcomes and patient satisfaction.	2010-09-07	20859458
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.	2010-09	20690781
Recommendations for management of diabetes during Ramadan: update 2010.	2010-08	20668157
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.	2010-08	20590741
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.	2010-08	20571352
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.	2010-07-09	21437091
Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.	2010-07-01	20703380
The evolving place of incretin-based therapies in type 2 diabetes.	2010-07	20130920
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.	2010-05-10	21437082
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.	2010-03-29	21437074
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.	2010-03-24	20448799
The physiologic role of incretin hormones: clinical applications.	2010-03	20382839
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.	2010-03	20151999
Incretin concepts.	2010-02	20103551
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.	2010-01	20082581
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.	2010-01	20040339
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.	2010	21701614
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).	2010	20652060
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.	2009-12	19758359
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.	2009-11	22112254
Incretin-based therapies: viewpoints on the way to consensus.	2009-11	19875556
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.	2009-11	19793357
Efficacy and safety of incretin based therapies: clinical trial data.	2009-10-06	19801363
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.	2009-10-06	19801361
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.	2009-10	19650752
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.	2009-10	19622714
New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.	2009-09-29	19783765
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.	2009-09-28	19780719
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.	2009-09	19478198
Alogliptin: a new addition to the class of DPP-4 inhibitors.	2009-07-21	21437125
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.	2009-07-20	19619327
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.	2009-07-17	19427871
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.	2009-06	19707284
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.	2009-06	19371350
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.	2009-05	19208898
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.	2009-03-01	19217790
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.	2009-03	19259628
Diabetes treatment.	2009-03	19246581
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.	2009-02	19191685
Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.	2009-01	19179812

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. Can be taken with or without food. Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:53:14 GMT 2025` Edited by `admin` on `Wed Apr 02 09:53:14 GMT 2025`
Record UNII	JHC049LO86
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALOGLIPTIN [MI]

Preferred Name

English

ALOGLIPTIN

Official Name

English

Alogliptin [WHO-DD]

Common Name

English

ALOGLIPTIN [VANDF]

Common Name

English

alogliptin [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A10BH04